GSK bets $2.1bn on Boston-based biopharma company
01-06-2022
Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation
13-12-2021
GSK responds to Teva’s ‘skinny’ label rehearing petition
09-12-2021
Willy Barton / Shutterstock.com
GlaxoSmithKline (GSK) has agreed to acquire California-based biopharma company Sierra Oncology for $1.9 billion, in a move that bolsters the UK company’s cancer business.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
GSK, GlaxoSmithKline, biopharma, cancer, oncology, Sierra Oncology, M&A, mergers and acquisitions
